Mortality and causes of death in systemic lupus erythematosus over the last decade: Data from a large population-based study
- PMID: 36774306
- DOI: 10.1016/j.ejim.2023.02.004
Mortality and causes of death in systemic lupus erythematosus over the last decade: Data from a large population-based study
Abstract
Objective: To assess mortality rates (MRs), standardized mortality ratios, and causes of death in systemic lupus erythematosus (SLE) in a population-based study.
Methods: We analyzed linked administrative health databases of the Veneto Region (Italy, 4,900,000 residents). SLE was defined by any hospital diagnosis or healthcare copayment exemption for SLE. We analyzed mortality from January 1st, 2012, until December 31st, 2021. MRs per 1000 were stratified by year, sex, and age group. Standardized mortality ratios were derived by comparing MRs of the general regional population. Causes of death were coded using the ICD-10 coding system and they were grouped in: SLE, infectious diseases, cardiovascular diseases (CVD), cancer, or others.
Results: Among 4283 SLE prevalent cases, 603 deaths occurred, corresponding to an average annual standardized MR of 18.6 per 1000 person/year (95% CI 17.0-20.2). Out of 1092 incident SLE patients, 90 died with a peak in the first year after diagnosis (MR 26.5 per 10,000 person/month). Standardized mortality ratio was 2.65 (95% CI 2.13-3.26) overall, and highest among younger patients (<45 years: 5.59, 95% CI 2.05-12.4). Five- and 8-year survival were 91% and 89%, respectively. About half of the deaths had CVD or cancer as underlying cause, whereas infections were less frequently reported.
Conclusions: Although the medium-term survival since diagnosis is good, SLE mortality is still higher than that of the general population, especially in youngest patients. Nowadays, CVD seems to be the major cause of deaths in SLE, whereas infections account for a low proportion of deaths, at least in Western countries.
Keywords: Cancer; Cardiovascular diseases, Infections; Mortality; Standardized mortality ratio, Causes of death; Survival; Systemic lupus erythematosus.
Copyright © 2023 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest All Authors declare they have no competing interests to report.
Comment in
-
Mortality and causes of death in systemic lupus erythematosus revisited.Eur J Intern Med. 2023 Jun;112:27-28. doi: 10.1016/j.ejim.2023.04.001. Epub 2023 Apr 8. Eur J Intern Med. 2023. PMID: 37037722 No abstract available.
Similar articles
-
Good survival rates in systemic lupus erythematosus in southern Sweden, while the mortality rate remains increased compared with the population.Lupus. 2019 Oct;28(12):1488-1494. doi: 10.1177/0961203319877947. Epub 2019 Sep 24. Lupus. 2019. PMID: 31551031
-
Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort.J Rheumatol. 2014 Apr;41(4):680-7. doi: 10.3899/jrheum.130874. Epub 2014 Feb 15. J Rheumatol. 2014. PMID: 24532834 Free PMC article.
-
Mortality and causes of death among incident cases of systemic lupus erythematosus in Finland 2000-2008.Lupus. 2014 Nov;23(13):1430-4. doi: 10.1177/0961203314543919. Epub 2014 Jul 23. Lupus. 2014. PMID: 25057036
-
Mortality in patients with systemic lupus erythematosus: A meta-analysis of overall and cause-specific effects.Lupus. 2024 Aug;33(9):929-937. doi: 10.1177/09612033241257134. Epub 2024 May 21. Lupus. 2024. PMID: 38769901
-
Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: A systematic review and Meta-analysis.Int Immunopharmacol. 2021 May;94:107466. doi: 10.1016/j.intimp.2021.107466. Epub 2021 Feb 23. Int Immunopharmacol. 2021. PMID: 33636561
Cited by
-
Antiphospholipid Antibodies Are Major Risk Factors for Non-Thrombotic Cardiac Complications in Systemic Lupus Erythematosus.Biomedicines. 2024 Feb 27;12(3):530. doi: 10.3390/biomedicines12030530. Biomedicines. 2024. PMID: 38540143 Free PMC article.
-
Clinical Outcomes of Patients with SLE Treated with Belimumab, Without Versus With Prior Immunosuppressant Use: a US Claims Database Study.Rheumatol Ther. 2025 Aug;12(4):679-694. doi: 10.1007/s40744-025-00774-6. Epub 2025 Jun 17. Rheumatol Ther. 2025. PMID: 40528076 Free PMC article.
-
New Mechanisms and Therapeutic Targets in Systemic Lupus Erythematosus.MedComm (2020). 2025 Jun 9;6(6):e70246. doi: 10.1002/mco2.70246. eCollection 2025 Jun. MedComm (2020). 2025. PMID: 40491969 Free PMC article. Review.
-
Trends in Systemic Lupus Erythematous Mortality in the United States, 1999-2022.ACR Open Rheumatol. 2025 Jun;7(6):e70057. doi: 10.1002/acr2.70057. ACR Open Rheumatol. 2025. PMID: 40528666 Free PMC article.
-
Accumulation of Microvascular Target Organ Damage in Systemic Lupus Erythematosus Patients Is Associated with Increased Cardiovascular Risk.J Clin Med. 2024 Apr 8;13(7):2140. doi: 10.3390/jcm13072140. J Clin Med. 2024. PMID: 38610905 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical